GA NCORP

NCORP Trials

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Status
Active
Cancer Type
Unknown Primary
Trial Phase
Phase I
Phase II
Eligibility
18 to 100, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT02658890
Protocol IDs
CA017-003 (primary)
NCI-2016-00153
2015-004914-79
Study Sponsor
Bristol-Myers Squibb

Summary

The purpose of the study is to determine safety, tolerability, pharmacokinetics and

pharmacodynamics of BMS-986205 when combined with Nivolumab [an anti-Programmed cell

Death-1(anti-PD1) antibody] in patients with advanced cancers.

Treatment Sites


Georgia Cancer Specialists - CenterPointe
1100 Johnson Ferry Road
Suite 600
Sandy Springs, GA 30342
Anila Lokhandwala
404-256-4777 ext 9242
www.gacancer.com

Doctors:

Rodolfo E. Bordoni MD
Pradeep C. Jolly MD

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
Northside Hospital Central Research Department
404-303-3355
www.northside.com

Study Coordinator:
Anila Lokhandwala
404-256-4777 x9242

Doctors:

Rodolfo E. Bordoni MD
Nishan H. Fernando MD
Pradeep C. Jolly MD